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Abstract
Background: Fibromyalgia (FM) is characterized by chronic, widespread muscular pain and tenderness and is generally 
associated with other somatic and psychological symptoms. Further, circulatory levels of proinflammatory cytokines 
(IL-1β, TNF-α, and IL-6) may be altered in FM patients, possibly in association with their symptoms. Recently, rises in BMI 
have been suggested to contribute to increased circulating levels of proinflammatory cytokines in FM patients. Our 
aim was to measure the circulatory levels of proinflammatory cytokines to determine the influence of BMI on these 
levels in FM patients and healthy volunteers (HVs). In Spanish FM patients (n = 64) and HVs (n = 25), we measured BMI 
and serum concentrations of proinflammatory cytokines by capture ELISA.
Findings: There were significant differences in BMI levels between FM patients (26.40 ± 4.46) and HVs (23.64 ± 3.45) 
and significant increase in IL-6 in FM patients (16.28 ± 8.13 vs 0.92 ± 0.32 pg/ml) (P < 0.001). IL-1β and TNF-α decreased 
in FM patients compared with HVs. By ANCOVA, there was no significant association between BMI and TNF-α (F = 0.098, 
p = 0.75) or IL-6 (F = 0.221, p = 0.63) levels in FM patients.
Conclusions: Our analysis in FM patients of BMI as a covariate of proinflammatory cytokines levels showed that serum 
TNF-α and IL-6 levels are independent of BMI. Further studies are necessary to dissect these findings and their 
implication in future therapeutic approaches for FM patients.
Introduction
F i b r o m y a l g i a  ( F M )  i s  a  c o m m o n ,  c h r o n i c ,  w i d e s p r e a d
pain syndrome that primarily affects the joints and mus-
cles and is generally associated with other somatic and
psychological symptoms, including fatigue, poor sleep,
c o g n i t i v e  d i f f i c u l t i e s ,  a n d  s t r e s s  [ 1 ] .  F M  p a t i e n t s  a r e
highly sensitive to painful and innocuous stimuli, includ-
ing touch, heat, cold, chemicals, light, sound, and smell
[2].
Although heightened pain sensitivity is a hallmark of
FM, little is known about the factors (genetic and other-
wise) that contribute to the development of this disease.
Recently, some reports have noted alterations in proin-
flammatory cytokine levels in the serum and biopsies of
FM patients [3,4], which might be associated with disease
symptoms [5-7].
Cytokines in fibromyalgia
Clinical studies have generated evidence that FM is asso-
ciated with immune dysregulation of circulatory levels of
proinflammatory cytokines, effecting the neural dysfunc-
tion of pain-related neurotransmitters [8]. Cytokines,
depending on their concentration, induce symptoms,
such as fatigue, fever, sleep, pain, and myalgia [9], all of
which develop in FM patients.
Alterations in proinflammatory cytokine levels have
been observed in the serum and biopsies of FM patients
[3,4]. In addition, increased levels of IL-1Ra and IL-6 have
been found in the supernatants of cells from FM patients
in vitro stimulation and cellular proliferation studies [7].
Until recently, no infectious or degenerative event that
was responsible for the variation in these levels had been
identified in FM patients, although factors, such as obe-
sity, can cause these alterations.
BMI and inflammatory response
Obesity contributes to FM-related symptoms [10-14].
According to clinical guidelines that have been proposed
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by the National Institutes of Health, subjects are catego-
rized as "normal" (BMI less than 25), "overweight" (BMI
over 25 but less than 30), and "obese" (BMI greater than
30) [15].
Further, obesity alone is a risk factor for chronic pain
disorders in general; for example, primary headaches are
more common in obese individuals [16]. Additionally,
recent evidence also suggests that obesity is characterized
by a low-grade chronic inflammatory state, reflected by
elevated levels in several serum inflammatory markers,
such as interleukin-6 (IL-6) and C-reactive protein (CRP)
[17].
The aim of this study was to measure circulatory levels
of IL-1β, TNF-α, and IL-6 in FM patients and determine
the influence of BMI as a covariate on the levels of these
cytokines statistically.
Materials and methods
The study design and protocol were reviewed and
approved by the Ethics Committee of the Hospital Uni-
versitario Miguel Servet in Zaragoza, Spain, in accor-
dance with the Declaration of Helsinki and the
Nuremberg Code. All the patients in the study granted
their informed consent.
Fibromyalgia patients
Sixty-four female outpatients, aged 25 to 60 years (47.0 ±
8.48 years)--all of whom were members of the Aragonese
Fibromyalgic and Chronic Fatigue Association (ASAFA)
in Zaragoza, Spain--were recruited into the study.
At study entry, all recruited patients underwent a com-
plete medical history, physical examination, and labora-
tory tests. The inclusion criterion was fibromyalgia that
had been diagnosed 2 to 3 years ago, based on the current
ACR diagnostic criteria [18]. Exclusion criteria were
acute infectious diseases in the previous 3 weeks; past or
present neurological, psychiatric, metabolic, autoim-
mune, allergy-related, dermatital or chronic inflamma-
tory disease; medical conditions that required
glucocorticoid treatment; past or current substance
abuse or dependence; and pregnancy or current breast-
feeding. Sixty-four potential participants met the inclu-
sion criteria and were enrolled into the study.
Healthy volunteers
Twenty-five healthy volunteers (HVs) were included in
the study matching the age range (44.96 ± 10.01 years),
gender, ethnicity (Spanish), and demographics (comple-
tion of at least 9 years of education and part of the middle
socioeconomic class) of the recruited female FM sub-
jects. HVs had no signs or symptoms of FM and were free
of any medication for at least 3 weeks before the study
began (based on blood and urine collection). HVs and FM
patients submitted written informed consent before the
studies began.
BMI determinatión
Body mass index (BMI) was calculated for each partici-
p a n t  ( B M I  =  b o d y  w e i g h t  [ K g ] / h e i g h t  [ m ] 2). Subjects
were categorized as "normal" (BMI less than 25), "over-
weight" (BMI over 25 but less than 30), and "obese" (BMI
greater than 30), per the clinical guidelines of the
National Institutes of Health [15]. Body weight was mea-
sured using a standard Seca Beam Balance (Seca GmBH
& Co Kg, Hamburg, Germany) as the reference instru-
ment.
Sample Collection
Blood was drawn between 8:00-9:00 A.M., and 20-mL
blood samples were collected in separate sterile tubes
that contained or lacked anti-clotting agents. Serum was
obtained by centrifuging the blood samples at 272 × g for
10 min; 1-ml aliquots were stored at -70°C until use.
These aliquots were used to measure the serum levels of
cytokines. All samples were handled individually in a
double-blind fashion.
Cytokine quantification by capture ELISA
Quantitative cytokine assays were performed by standard
capture enzyme-linked immunosorbent assay using
Quantikine kits, for which the validated detection limits
were 0.5-1000 pg/mL for TNF-α, 3.91-250 pg/mL for IL-
1μ, and 0.7-300 pg/mL for IL-6. All kits, antibodies, and
recombinant cytokines were purchased from R&D Sys-
tems (Minneapolis, MN). The assays were performed
according to the manufacturer's instructions http://
www.rndsystems.com, and absorbance was measured at λ
= 492 nm on a spectrophotometer (Sunrise, Tecan). All
samples were measured twice (in triplicate), from which
the mean was calculated. The inter- and intra-assay vari-
ability was < 7% and < 5%, respectively.
Statistical analysis
All values are expressed as mean ± standard deviation.
Comparisons between healthy volunteers and patients
were made by non parametric Mann-Whitney test for IL-
6.
The student test (t) was used to analyze the differences
in: a) BMI levels between healthy volunteers and patients;
b) proinflammatory cytokine levels between BMI subsets
(normal, overweight, and obese); and c) TNF-α levels
between healthy volunteers and patients. Analysis of
covariance (ANCOVA) was used to analyze the differ-
ences in proinflammatory cytokine levels and the covari-
ate factor (BMI). The analysis was performed with Graph
Pad (San Diego, CA, USA). In all tests, the null hypothesis
was rejected at the 0.05 level.Hernandez et al. BMC Research Notes 2010, 3:156
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Results
Clinical parameters
Clinical and laboratory assessments (i.e., complete blood
count, blood chemistry, and complete urinalysis) of the
fibromyalgia and control subjects fell within normal ref-
erence value ranges. No statistical differences were
observed between the groups (data not shown).
Cytokine measurements
The quantification of serum levels of proinflammatory
cytokines in the FM and control groups by capture ELISA
is shown in Table 1. IL-6 levels in FM patients were signif-
icantly higher than in HVs (Significance: p ≤0.001, Mann-
Whitney test). TNF-α levels differed significantly
between patients and HVs (t = 10.5, df = 87, p < 0.001).
Although serum IL-1β levels were significantly lower in
FM patients than in HVs, they were below the sensitivity
levels, as indicated by the manufacturer (3.91 pg/mL);
therefore, they were considered nondetectable (ND).
BMI
The mean BMI values for the FM and HVs are shown in
Table 1. Patients had significant BMI values with respect
to HVs (t = 5.05, df = 87, p < 0.001). FM patients and HVs
were classified as normal (FM = 24; HV = 17) and over-
weight (FM = 19; HV = 3). There were no significant dif-
ferences in proinflammatory cytokine levels between
BMI subsets (data not shown).
Association between cytokine levels and BMI
Because BMI differed between HVs and FM patients, we
performed ANCOVA to determine whether this covari-
able influenced cytokine levels. By ANCOVA, there was
no significant association between BMI and TNF-α (F =
0.098. p = 0.75) or IL-6 (F = 0.221, p = 0.63) levels.
Discussion
Currently, the diagnosis of fibromyalgia is reached after
eliminating the possibility of rheumatic and psychiatric
diseases, which represents a 2 or 3 year period before a
specific diagnosis can be made. To attain a better under-
standing of this clinical condition and improve the quality
of life for patients, we recommend that the variables that
regulate FM be investigated, as well as the association
between them. In this study, we measured proinflamma-
tory cytokine levels and BMI.
Our study showed that FM patients had different circu-
latory levels of IL-6, TNF-α, and IL-1β compared with
HVs. IL-6 increased significantly, which is consistent with
other clinical studies [3]; further, other reports have
noted an association of high levels of IL-6 (> 1 pg/mL)
with painful events, surgical procedures and certain psy-
chiatric disorders [19,20], as well as between fatigue and
pain in animal models [21]; These findings suggests that
IL-6 may regulates the clinical symptoms that develop in
patients with FM.
TNF-α levels decreased in FM patients significantly in
our study, in contrast to reports by Wang et al., Üçeyler et
al., and Wallace et al., wherein TNF-α levels rose in
untreated patients in one of the studies and were
unchanged in the other reports [7,22,23]. This discrep-
ancy might be due to variations in inclusion criteria for
the patients, sample size, age, BMI, and detection meth-
ods [7,22,23].
I n  o u r  s t u d y ,  I L - 1 β  l e v e l s  i n  F M  p a t i e n t s  w e r e  n o t
within the range of detection, suggesting that they are sig-
nificantly lower. Other reports, such as a study by Wallace
et al., found that IL-1β levels in FM patients did not differ
significantly from those in HVs, although levels of the sol-
uble receptor for this cytokine (IL-1Ra) were significantly
elevated [7]. These results suggest that IL-1Ra may
induce a decrease in circulatory IL-1β to undetectable
levels, as in our study.
The variations in cytokine levels in this study might
reflect the activation of specific intracellular mecha-
nisms. In healthy individuals, the levels of proinflamma-
tory cytokines are controlled by diverse mechanisms, one
of which involves the IL-6 receptor and gp130 protein.
When IL-6 binds to its receptor, a mechanism is triggered
blocking Janus Kinase signal and activator of transcrip-
Table 1: Demographics; Body Mass Index; Cytokine levels in woman with fibromyalgia and Healthy volunteers
Healthy Volunteers Female (n = 25) FM Female (n = 64) FM vs. Healthy Volunteers
Age (years) 44.96 ± 10.01 47.07 ± 8.48 N.S.
BMI (kg/m2) 23.64 ± 3.45 26.40 ± 4.46 *
TNF-α (pg/mL) 35.73 ± 0.72 20.42 ± 7.24 *
IL-1 (pg/mL) 17.04 ± 0.62 N.D. N.A.
IL-6 (pg/mL) 0.92 ± 0.32 16.28 ± 8.13 *
Values are presented as mean (± SD) except where otherwise noted.
BMI = Body Mass Index; FM = Fibromyalgia patients; IL = Interleukin; N.D. = nondetectable; N.S. = not significant; N.A. = nonapplicable; TNF-
α = Tumor Necrosis Factor - alpha.
t = p < 0.001Hernandez et al. BMC Research Notes 2010, 3:156
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tion (JAK/STAT) mediated transcription of IL-1 and
TNF-α [24], decreasing their levels in circulation [25,26].
This mechanism might explain the differential levels of
proinflammatory cytokines that were observed.
Few studies have analyzed the association between BMI
and cytokine levels in FM patients. One such study by
Okifuji et al., reported a correlation between IL-6 levels
and obesity, but 50% of their clinical samples comprised
patients whose BMI ≥ 30 [11]. In contrast, we analyzed
BMI as a covariate of variations in serum levels of IL-6
and TNF-α and found that ANCOVA test failed to reveal
any significance, implying that the changes in cytokine
levels were independent of BMI.
White adipose tissue regulates the production of TNF-
α and IL-6, which induces low-grade inflammation
[27,28]. Individual fat quantities can be inferred from
waist circumference [15] but not BMI. The inclusion of
waist circumference modifies the risk factor that is
induced by the BMI with regard to the inflammatory and
painful phenomena that are associated with obesity, such
as fibromyalgia [13,16,29].
We conclude in this study, that variations in proinflam-
matory cytokines levels in FM patients are independents
from BMI and the mechanisms underlying this response
maybe a direct consequence of biochemical and func-
tional alterations in FM patients. Further studies on fibro-
myalgia should consider BMI and waist circumference to
develop a more accurate indicator of the amount of adi-
pose tissue as a source of production of proinflammatory
cytokines. The limitations of this study were the number
of participants and the failure to measure waist circum-
ference in the participants. Thus, to validate the diagnos-
tic value of this clinical finding, a multicenter,
longitudinal study must be performed in a large pool of
homogeneous patients.
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